Pooled statistical meta-analyses and systematic reviews aggregating thousands of patients across multiple randomized controlled trials to measure true effect size. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
Tirzepatide 15 mg and CagriSema achieve the greatest weight reduction, including ≥ 20% body weight loss.
The use of GLP-1 RAs is significantly associated with an increased risk of hair loss.
Obesity drugs produce variable weight loss at one year, with larger benefits generally accompanied by greater harms and discontinuation.
Lean mass loss during significant weight reduction is substantial, and the proportion of weight lost as lean mass is broadly comparable between incretin-based pharmacotherapy and lifestyle interventions.
Tirzepatide and Semaglutide_SC are most effective for clinically meaningful weight loss.
In this NMA, tirzepatide 10 and 15 mg were associated with improved efficacy versus liraglutide, improved or comparable efficacy versus semaglutide, and all interventions had a generally comparable safety profile for achieving.
Of 7705 unique records, 41 articles representing 64 RCTs were included in the meta-analysis.
In this NMA, tirzepatide appeared to be superior to semaglutide in both body weight reduction and improvement of glycemic indices.
CONCLUSION: This meta-analysis identified several risk factors associated with AGA presence and progression, including a family history of AGA, smoking, alcohol consumption, insufficient or poor-quality sleep,...
This meta-analysis suggests that elevated SIRI is associated with poorer OS and PFS in glioma patients, although this association was not consistently observed across all subgroups, particularly in European populations. These findings highlight the need for further validation with standardized cut-off values in diverse populations.
In this meta-analysis, machine learning models showed moderate predictive performance for short-term mortality in sepsis. Among complications, SAE and SIC had the strongest evidence and best performance, whereas SAD showed limited utility. Evidence for long-term mortality was extremely scarce.
Low-dose GMRx2 provides superior BP reduction and a well-tolerated safety profile in patients with mild to moderate high blood pressure.
Tirzepatide was associated with numerically greater weight loss across available studies, though high heterogeneity and observational data limit causal inference.
Semaglutide significantly improves BMI and lipid profiles in PCOS, particularly at higher doses, and in obese patients.
LPP is significantly associated with autoimmune disorders, thyroid diseases, and skin cancer.
Besides, VECs employ both disease-specific ligand-receptor networks to recruit immune cells and remodel stromal niches, alongside conserved mechanisms preserving vascular-immune crosstalk across pathologies.
No significant statistical difference was found between GLP-1 agonists and other obesity and diabetes drugs regarding suicide/suicidal ideation.
These findings highlight their potential as a future adjunctive, non-pharmaceutical therapy for the roughly 9.6 million children patients affected in the United States.
Additionally, there was a significantly higher incidence of herpes simplex infections in eczema patients with target-selective JAK inhibitors, while no increased risk was observed with herpes zoster.
Retatrutide offers superior weight loss efficacy but with a higher AE risk.
An updated framework specific to GAD is therefore needed to clarify the underlying cognitive mechanisms underlying this condition.
These findings confirm that AA is associated with a heightened risk of various immune-mediated conditions.
Original protocol (10.1002/14651858.CD015092) published in September 2022.
Available evidence is insufficient to establish a definitive association between OSA and SCD.
Tirzepatide was effective in full symptom relief of obstructive sleep apnea syndrome and metabolic dysfunction-associated steatohepatitis.
However, more long-term randomized controlled trials are needed to confirm these findings and further assess its effectiveness.
SERM therapy is associated with significantly improved levels of TT, LH, and FSH in hypogonadal men compared to placebo, and significantly enhanced levels of LH and FSH compared to T gel.
GLP-1 RA or GIP/GLP-1RA are not cost-effective for obesity treatment in China currently.
This meta-analysis demonstrated that MADs effectively reduced AHI severity and increased min SpO2 in OSA patients.
Regarding safety, no difference in the side effects (AEs) was observed between two groups.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
